Dilation of colonic strictures by intralesional injection of infliximab in patients with Crohn's colitis

Inflammatory Bowel Diseases

Volumn 14, Issue 2, 2008, Pages 213-216

  Swaminath, Arun ^a   Lichtiger, Simon ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

Colonic stricture; Crohn's disease; Infliximab

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; STEROID;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CASE REPORT; COLON DILATATION; COLON STENOSIS; COLON STRICTURE; COLONOSCOPY; CROHN DISEASE; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; HEMICOLECTOMY; HUMAN; LOW DRUG DOSE; MALE; PRIORITY JOURNAL; SCLEROTHERAPY; SMALL INTESTINE OBSTRUCTION; STEROID THERAPY; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT REFUSAL;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COLONIC DISEASES; CROHN DISEASE; FEMALE; HUMANS; ILEAL DISEASES; INJECTIONS, INTRALESIONAL; INTESTINAL OBSTRUCTION; MALE; MIDDLE AGED; RECTAL DISEASES;

EID: 39649115628     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20318     Document Type: Article

References (31)

1. Loftus EV Jr. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126:1504-1517.
2. Linares L, Moreira LF, Andrews H, Allan RN, Alexander-Williams J, Keighley MR. Natural history and treatment of anorectal strictures complicating Crohn's disease. Br J Surg. 1988;75:653-655.
3. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis. 2002;8:244-250.
4. Singh VV, Draganov P, Valentine J. Efficacy and safety of endoscopic balloon dilation of symptomatic upper and lower gastrointestinal Crohn's disease strictures. J Clin Gastroenterol. 2005;39:284-290.
5. Lavy A. Triamcinolone improves outcome in Crohn's disease strictures. Dis Colon Rectum. 1997;40:184-186.
6. Couckuyt H, Gevers AM, Coremans G, Hiele M, Rutgeerts P. Efficacy and safety of hydrostatic balloon dilatation of ileocolonic Crohn's strictures: a prospective longterm analysis. Gut. 1995;36:577-580.
7. Futami K, Arima S. Role of strictureplasty in surgical treatment of Crohn's disease. J Gastroenterol. 2005;40(Suppl 16):35-39.
8. Taschieri AM, Cristaldi M, Elli M, Danelli PG, Molteni B, Rovati M, Bianchi Porro G. Description of new "bowel-sparing" techniques for long strictures of Crohn's disease. Am J Surg. 1997;173:509-512.
9. Yamamoto T. Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol. 2005;11:3971-3979.
10. Verrecchia F, Mauviel A. Transforming growth factor-beta signaling through the Smad pathway: role in extracellular matrix gene expression and regulation. J Invest Dermatol. 2002;118:211-215.
11. Zeeh JM, Riley NE, Hoffmann P, Reinshagen M, Goebell H, Gerken G. Expression of insulin-like growth factor binding proteins and collagen in experimental colitis in rats. Eur J Gastroenterol Hepatol. 2001;13:851-858.
12. McKaig BC, Hughes K, Tighe PJ, Mahida YR. Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts. Am J Physiol Cell Physiol. 2002;282:C172-C182.
13. Breysem Y, Janssens JF, Coremans G, Vantrappen G, Hendrickx G, Rutgeerts P. Endoscopic balloon dilation of colonic and ileo-colonic Crohn's strictures: long-term results. Gastrointest Endosc. 1992;38:142-147.
14. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology. 1999;116:1029-1034.
15. Ramboer C, Verhamme M, Dhondt E, Huys S, Van Eygen K, Vermeire L. Endoscopic treatment of stenosis in recurrent Crohn's disease with balloon dilation combined with local corticosteroid injection. Gastrointest Endosc. 1995;42:252-255.
16. Thomas-Gibson S, Brooker JC, Hayward CM, Shah SG, Williams CB, Saunders BP. Colonoscopic balloon dilation of Crohn's strictures: a review of long-term outcomes. Eur J Gastroenterol Hepatol. 2003;15:485-488.
17. Biancone L, Cretella M, Tosti C, Palmieri G, Petruzziello C, Geremia A, Calabrese E, Pallone F. Local injection of infliximab in the postoperative recurrence of Crohn's disease. Gastrointest Endosc. 2006;63:486-492.
18. Motomura Y, Kanbayashi H, Khan WI, Deng Y, Blennerhassett PA, Margetts PJ, Gauldie J, Egashira K, Collins SM. The gene transfer of soluble VEGF type I receptor (Flt-1) attenuates peritoneal fibrosis formation in mice but not soluble TGF-beta type II receptor gene transfer. Am J Physiol Gastrointest Liver Physiol. 2005;288:G143-G150.
19. Wengrower D, Zannineli G, Pappo O, Latella G, Sestieri M, Villanova A, Faitelson Y, Pines M, Goldin E. Prevention of fibrosis in experimental colitis by captopril: the role of tgf-beta1. Inflamm Bowel Dis. 2004;10:536-545.
20. Scheinfeld B. Verapamil inhibitors interleukin-1b meidated hyperplasia of human intestinal smooth cells. Gastroenterology. 1994;106:A768.
21. Sheibanie AF, Yen JH, Khayrullina T, Emig F, Zhang M, Tuma R, Ganea D. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23→IL-17 axis. J Immunol. 2007;178:8138-8147.
22. Hurst RD, Michelassi F. Strictureplasty for Crohn's disease: techniques and long-term results. World J Surg. 1998;22:359-363.
23. Tichansky D, Cagir B, Yoo E, Marcus SM, Fry RD. Strictureplasty for Crohn's disease: meta-analysis. Dis Colon Rectum. 2000;43:911-919.
24. Tonelli F, Ficari F. Strictureplasty in Crohn's disease: surgical option. Dis Colon Rectum. 2000;43:920-926.
25. Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg. 2000;231:38-45.
26. Yamamoto T, Allan RN, Keighley MR. An audit of gastroduodenal Crohn disease: clinicopathologic features and management. Scand J Gastroenterol. 1999;34:1019-1024.
27. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549.
28. Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand J Gastroenterol. 2006;41:1064-1072.
29. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 2002;46:3151-3158.
30. Siegel CA, Hur C, Korzenik JR, Gazelle GS, Sands BE. Risks and benefits of infliximab for the treatment of Crohn's disease. Clin Gastroenterol Hepatol. 2006;4:1017-1024; quiz 976.
31. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol. 2004;2:542-553